Suppr超能文献

海地未经治疗的受试者痰液中可检测到的结核分枝杆菌细胞及其在治疗开始后比例的增加。

Differentially Detectable Mycobacterium tuberculosis Cells in Sputum from Treatment-Naive Subjects in Haiti and Their Proportionate Increase after Initiation of Treatment.

机构信息

Center for Global Health, Weill Cornell Medicine, New York, New York, USA.

Department of Microbiology & Immunology, Weill Cornell Medicine, New York, New York, USA.

出版信息

mBio. 2018 Nov 20;9(6):e02192-18. doi: 10.1128/mBio.02192-18.

Abstract

Recent reports indicate that the sputum of 80% or more of treatment-naive subjects with tuberculosis recruited in England or South Africa contained more viable cells detected by limiting dilution (LD) in liquid culture than detected as CFU. Efforts to generate such differentially detectable (DD) populations have been difficult to reproduce, and the LD assay is prone to artifact. Here, we applied a stringent version of the LD assay to sputum from 33 treatment-naive, HIV-negative Haitian subjects with drug-sensitive tuberculosis (TB) and to a second sputum sample after two weeks of standard treatment with isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) for 13 of these subjects. Twenty-one percent had statistically defined levels of DD in their pretreatment sputum at an average proportional excess over CFU of 3-fold. Sixty-nine percent of those who received HRZE had statistically defined levels of DD in their sputum, and of these, the mean proportionate excess over CFU was 7.9-fold. Thus, DD is detectable in pretreatment sputum from a significant proportion of subjects in the Western Hemisphere, and certain drugs or drug regimens, while reducing CFU, may at the same time increase the proportional representation of DD among the surviving bacilli. Monitoring DD may improve our ability to predict the efficacy of efforts to shorten treatment. Measurement of the reduction in CFU in sputum of patients with TB up to 2 weeks after the initiation of treatment is the gateway test for a new TB treatment. Reports have suggested that CFU assays fail to detect the majority of viable cells in sputum samples from the majority of patients when the number of is estimated by limiting dilution (LD). In an effort to avoid potential methodologic confounders, we applied a modified version of the LD assay in a study of a geographically distinct population. We confirmed that differentially detectable (DD) is often found before treatment, albeit at lower proportionate levels than in earlier reports. Strikingly, the prevalence and proportionate representation of DD increased during standard treatment. Sublethal exposure to certain antibiotics may help generate DD cells or enrich their representation among the surviving bacteria, and this may contribute to the need for prolonged treatment with those agents in order to achieve durable cures.

摘要

最近的报告表明,在英国或南非招募的未经治疗的结核病患者中,有 80%或更多的患者的痰液中,通过液体培养中的限量稀释(LD)检测到的活菌细胞比 CFU 检测到的更多。试图产生这种可差异检测(DD)的群体一直很困难,而且 LD 检测容易出现假象。在这里,我们应用严格的 LD 检测方法对 33 名未经治疗、HIV 阴性、患有药物敏感型结核病(TB)的海地患者的痰液进行检测,并对其中 13 名患者在接受异烟肼、利福平、吡嗪酰胺和乙胺丁醇(HRZE)标准治疗两周后的第二次痰液样本进行检测。21%的患者在预处理痰液中具有统计学上定义的 DD 水平,其 CFU 平均超额 3 倍。在接受 HRZE 治疗的患者中,有 69%的患者在其痰液中具有统计学上定义的 DD 水平,其中 CFU 的平均超额比例为 7.9 倍。因此,在西半球的很大一部分患者的预处理痰液中可检测到 DD,并且某些药物或药物方案在减少 CFU 的同时,可能会同时增加存活细菌中 DD 的比例代表。监测 DD 可能会提高我们预测缩短治疗效果的能力。在开始治疗后 2 周内,测量结核病患者痰液中 CFU 的减少量是新结核病治疗的入门测试。报告表明,当通过限量稀释(LD)估计细菌数量时,CFU 检测无法检测到大多数患者的痰液样本中的大多数活菌。为了避免潜在的方法学混淆,我们在一项具有地理差异的人群研究中应用了 LD 检测的改良版本。我们证实,在治疗前通常可以发现可差异检测(DD),尽管其比例水平低于早期报告。引人注目的是,DD 的流行率和比例代表在标准治疗期间增加。亚致死暴露于某些抗生素可能有助于产生 DD 细胞,或在存活细菌中富集其代表,这可能是这些药物需要延长治疗以实现持久治愈的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a659/6247085/3b0c4dacaf3d/mbo0061841730001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验